Trending News

Caught in the Act: Practical and Legal Considerations When Executives’ Office Love Affair Exposed

Florida’s CHOICE Act Becomes Law, Enhancing Certain Non-Compete Agreements

Labor Secretary Lifts Abeyance on OFCCP Disability and Veteran Matters

In Case You Missed It: DOL Prohibited From Collecting Liquidated Damages in Wage & Hour Pre-Litigation Investigations

SEC’s New Concept Release on Foreign Private Issuer Standards

What Regulated Businesses Should Know About the Supreme Court’s Recent NEPA Decision

NEW ATDS BATTLEGROUND: Texas Passes HUGE NEW AMENDMENT to Its State Telemarketing Law Reviving The Risk of Autodialer Cases

Supreme Court Eliminates Heightened Discrimination Standard Under Title VII

Cleaning the Cupboard—Six More Decisions in One Day, and a Largely Harmonious Court - SCOTUS Today

U.S. Supreme Court Holds Majority-Group Plaintiffs Are Not Subject to a Heightened Evidentiary Standard Under Title VII

GlobeNewswire Biotech

Website

www.globenewswire.com

Featured Biotech Press Releases From GlobeNewswire

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
Posted On Wednesday, June 25, 2025
Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent
Posted On Wednesday, June 25, 2025
Hepion Pharmaceuticals Successfully Completes Application to the OTCQB
Posted On Wednesday, June 25, 2025
Eyenovia Announces Co-Branded Validator with Kinetiq
Posted On Wednesday, June 25, 2025
Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
Posted On Wednesday, June 25, 2025
Intelligent Bio Solutions and Spjotgard Drive Rapid Adoption of Fingerprint Drug Testing Across Scandinavia
Posted On Wednesday, June 25, 2025
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
Posted On Wednesday, June 25, 2025
DIMERx Awarded Up to $15M by NIDA Under NIH HEAL Initiative® to Advance DMX-101 as a Non-Addictive Oral Therapy for Chronic Pain
Posted On Wednesday, June 25, 2025
Arbor Biotechnologies Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors
Posted On Wednesday, June 25, 2025
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
Posted On Wednesday, June 25, 2025
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
Posted On Wednesday, June 25, 2025
Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer
Posted On Wednesday, June 25, 2025
Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)
Posted On Wednesday, June 25, 2025
Oncotelic Therapeutics Announces Publication of Landmark Study on TGFB2 Gene Methylation as a Positive Prognostic Marker in Pancreatic Cancer
Posted On Wednesday, June 25, 2025
Verano Unveils Bodega-Style Dispensary Experience at Zen Leaf Cave Creek in Phoenix
Posted On Wednesday, June 25, 2025
MetasTx Secures NCI Grant to Enable the Advancement of Dual-Track Strategy Against Metastatic Prostate Cancer
Posted On Wednesday, June 25, 2025
Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update
Posted On Wednesday, June 25, 2025
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit
Posted On Wednesday, June 25, 2025
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan
Posted On Wednesday, June 25, 2025
Actimed Therapeutics Enrolls First Patients in Phase 2a PROACT Study Programme to Assess S-pindolol benzoate in Obese Patients During and Post-GLP-1 Agonist Therapy
Posted On Wednesday, June 25, 2025
Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director
Posted On Wednesday, June 25, 2025
LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park
Posted On Wednesday, June 25, 2025
Cidara Announces Pricing of Upsized Public Offering of Common Stock
Posted On Tuesday, June 24, 2025
Glass House Brands Inc. Announces Voting Results Following Annual and Special Meeting
Posted On Tuesday, June 24, 2025
Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease
Posted On Tuesday, June 24, 2025

Print